Argenx Earnings Call Highlights Explosive Growth, Ocular Win

Argenx ((ARGX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Argenx’s latest earnings call struck a decisively upbeat tone as the company paired explosive top‑line growth with its first full year of operating profitability. Management acknowledged margin and spending pressures, but emphasized rapidly scaling VYVGART adoption, a pivotal win in ocular myasthenia gravis, and a strengthened balance sheet as foundations for long‑term value creation.

Revenue Surge and Scaling Profitability

Argenx delivered Q4 2025 product net sales of $1.3B and $4.2B for the full year, up 90% year over year as VYVGART demand accelerated globally. The company reported Q4 operating profit of $367M and $1.1B for the year, translating into net profit of $533M in Q4 and $1.3B for 2025, marking its first year of sustained operating profitability.

Balance Sheet Strength Fuels Growth Options

The company ended Q4 with $4.4B in cash, cash equivalents, and current financial assets, an increase of over $1B in twelve months. Management highlighted this cash position as key to funding commercial expansion, advancing its broad pipeline, and absorbing higher R&D investment without near‑term financing pressure.

Ocular MG Phase III Win Expands VYVGART’s Reach

In a major clinical milestone, the Phase III ADAPT OCULUS trial in ocular MG met its primary endpoint on the MGII patient‑reported ocular score, with VYVGART Hytrulo showing a mean improvement of 4.04 versus 1.99 on placebo at week four (p=0.012). The study showed clear benefits in diplopia and ptosis with a favorable safety profile, and Argenx plans to file a supplemental biologics application to add the indication.

MG and CIDP Adoption Underpins Commercial Momentum

Approximately 19,000 patients were on VYVGART treatment globally at year‑end 2025, underscoring strong uptake in generalized MG and chronic inflammatory demyelinating polyneuropathy. VYVGART is now the fastest‑growing and most‑prescribed biologic in MG, with six in ten biologic‑naïve MG patients starting on the drug and about 70% of users switching from oral therapies.

Prefilled Syringe and Access Tailwinds

The launch of the prefilled syringe has become a key driver of new starts and convenience, helping push the prescriber base to more than 4,700 globally, including a wave of new writers since the launch. A notable access win with UnitedHealthcare improved coverage for the prefilled syringe, lifting covered lives above 90% and supporting further adoption in both MG and CIDP.

Deep Pipeline and Next‑Generation FcRn Platform

Management spotlighted a growing immunology pipeline including four new molecules from its innovation platform and next‑generation FcRn candidates ARGX‑213 and ARGX‑124. First‑in‑class programs such as ARGX‑121, targeting IgA, and ARGX‑118, targeting Galectin‑10, are also advancing, with three Phase I programs expected to progress in 2026 and an empasiprubart MMN data readout planned for Q4.

Execution Against Vision 2030 Strategy

Argenx delivered 2025 combined R&D and SG&A expenses of $2.7B, in line with prior guidance, while investing heavily behind its “Vision 2030” roadmap. Strategic priorities include label expansions such as seronegative MG, new delivery modalities including an auto‑injector planned for 2027, and a disciplined approach to broadening indications for VYVGART and follow‑on assets.

Tax and Financial Discipline Amid Scaling

The company reported a year‑to‑date gross margin of roughly 11% with Q4 cost of sales at $150M, and noted that reported tax for Q4 and the full year benefited from nonrecurring items and foreign‑exchange effects. Looking ahead, Argenx guided to an effective tax rate in the low‑ to mid‑teens, while reiterating its focus on disciplined capital allocation.

Margin Headwinds from Low Gross Profit

Despite strong revenue growth, management acknowledged that the roughly 11% gross margin remains a structural challenge that limits operating leverage. The cost profile of current products means incremental growth does not fully translate into profit expansion, keeping margin improvement a longer‑term rather than near‑term story.

Rising Operating Expenses Pressure Near‑Term Margins

Total operating expenses reached $955M in Q4, up $149M versus Q3, with full‑year combined R&D and SG&A climbing to $2.7B, around 30% higher than 2024. Executives signaled that operating expenses will continue to rise in 2026, driven primarily by R&D, which could temper margin expansion even as revenues scale.

ALS Setback Reshapes Development Priorities

The company reported disappointing Phase IIa results for adimanebart in amyotrophic lateral sclerosis, which did not support further development in that indication. As a result, Argenx is halting ALS progression for the asset and reallocating resources toward areas where its FcRn and immunology platforms have clearer proof‑of‑concept.

Regulatory Hurdles in Graves Disease Program

In Graves disease, regulators have requested two trials rather than a single pivotal study, raising the bar for approval in this endocrine indication. The change adds time, cost, and regulatory risk to the program, reinforcing Argenx’s message that not all pipeline bets will progress on the same timeline as its core neuromuscular franchise.

Payer Dynamics and Seasonal Volatility Weigh on Visibility

While the ocular MG win is expected to expand VYVGART’s labeled market, management cautioned that payers had previously resisted off‑label use for ocular symptoms and may take one to two quarters post‑approval to fully adjust coverage. Seasonal Q1 factors, including insurance re‑verifications and winter storms, also create short‑term variability in patient starts and revenues.

Competitive Pressures in the MG Market

Argenx acknowledged new entrants and recent approvals in MG that are intensifying competition for patients and pricing. Management remains confident in VYVGART’s efficacy, safety, convenient dosing options, and evolving delivery formats, but investors were reminded that long‑term share and margins will be shaped by how this competitive landscape evolves.

Timing Uncertainty for Next‑Generation Assets

The company’s next‑generation FcRn candidates, including ARGX‑213 and ARGX‑124, are still in early‑stage development, and detailed timelines for Phase I readouts and registrational strategies have yet to be fully mapped out. While these assets present meaningful upside potential, management signaled that their financial contribution is more of a medium‑ to long‑term opportunity than an imminent growth driver.

Guidance and Milestones Signal Continued Aggressive Investment

Management reiterated 2025 figures of $4.2B in net product sales, a 90% year‑over‑year increase, with Q4 operating profit of $367M and full‑year operating profit of $1.1B supported by a $4.4B cash pile and an expected tax rate in the low‑ to mid‑teens. For 2026, Argenx plans to grow operating expenses at a similar percentage pace, advance three Phase I programs, push next‑gen FcRn assets and an auto‑injector toward 2027, and deliver key milestones including a May decision on seronegative MG, an ocular MG filing, and Q4 data for empasiprubart in MMN.

Argenx’s earnings call painted the picture of a company transitioning from a high‑potential story to an established commercial player, albeit with cost and execution challenges ahead. Robust VYVGART growth, clinical validation in ocular MG, and a fortified balance sheet underpin the bullish narrative, while investors will watch margins, payer behavior, and pipeline execution to gauge how durable this growth proves over the next phase.